Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.

Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.
复制标题

DOI:
10.1371/journal.pone.0090467
复制
发表时间:
2014
期刊:
影响因子:
3.7
通讯作者:
Klee EW
Klee EW
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Cousin MA;Ebbert JO;Wiinamaki AR;Urban MD;Argue DP;Ekker SC;Klee EW

文献摘要

参考文献

被引文献

相似文献

在美国,吸烟仍然是最可预防的死亡和过度医疗费用的原因,也是酗酒者死亡的主要原因。长期戒烟率很低,药物选择有限。美国食品和药物管理局(FDA)批准的重新定位药物可以有效地为临床医生提供新的治疗选择。我们开发了一个药物重新定位范例,使用斑马鱼幼体运动,并建立了预测的临床有效性,使用FDA批准的戒烟疗法。我们评估了39种经医生审查的尼古丁诱导的运动激活阻滞药物。我们进一步评估了候选药物改变乙醇反应,以及与伐尼克兰联合用于尼古丁反应衰减。六种药物特别抑制尼古丁反应。其中,阿扑吗啡和托吡酯阻断尼古丁和乙醇的反应。两者在布利斯独立性测试中均与伐尼克兰积极相互作用,表明潜在的协同相互作用,表明这些药物可用于II期戒烟临床试验。
Cigarette smoking remains the most preventable cause of death and excess health care costs in the United States, and is a leading cause of death among alcoholics. Long-term tobacco abstinence rates are low, and pharmacotherapeutic options are limited. Repositioning medications approved by the U.S. Food and Drug Administration (FDA) may efficiently provide clinicians with new treatment options. We developed a drug-repositioning paradigm using larval zebrafish locomotion and established predictive clinical validity using FDA-approved smoking cessation therapeutics. We evaluated 39 physician-vetted medications for nicotine-induced locomotor activation blockade. We further evaluated candidate medications for altered ethanol response, as well as in combination with varenicline for nicotine-response attenuation. Six medications specifically inhibited the nicotine response. Among this set, apomorphine and topiramate blocked both nicotine and ethanol responses. Both positively interact with varenicline in the Bliss Independence test, indicating potential synergistic interactions suggesting these are candidates for translation into Phase II clinical trials for smoking cessation.
DOI: 10.1093/ntr/ntn031
发表时间: 2009-03-01
影响因子: 4.7
作者:
Ebbert, Jon O.;Croghan, Ivana T.;Hurt, Richard D.
通讯作者: Hurt, Richard D.
DOI: 10.1001/jama.2013.283185
发表时间: 2014-01-08
影响因子: 120.7
作者:
Ebbert, Jon O.;Hatsukami, Dorothy K.;Croghan, Ivana T.;Schroeder, Darrell R.;Allen, Sharon S.;Hays, J. Taylor;Hurt, Richard D.
通讯作者: Hurt, Richard D.
DOI: 10.1016/j.neuropharm.2010.04.014
发表时间: 2010-09-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Buckley, Clare E.;Marguerie, Anita;Franklin, Robin J. M.
通讯作者: Franklin, Robin J. M.
DOI: 10.1016/j.brainres.2004.05.091
发表时间: 2004-09-03
期刊: BRAIN RESEARCH
影响因子: 2.9
作者:
Carey, RJ;DePalma, G;Huston, JP
通讯作者: Huston, JP
DOI: 10.1016/j.cell.2006.09.035
发表时间: 2006-11-03
期刊: CELL
影响因子: 64.5
作者:
Feng, Zhaoyang;Li, Wei;Xu, X. Z. Shawn
通讯作者: Xu, X. Z. Shawn